A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Trial details
- Registry ID
- NCT07766005
- Drugs studied
- SPY072, bimekizumab
TrialRedline tracks 4 clinical trials sponsored by Spyre Therapeutics, Inc.: 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)NCT07766005 | SPY072, bimekizumab | Recruiting | 2027-10Estimated |
| A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisNCT07012395 | SPY001, SPY002, SPY003 | Recruiting | 2027-06Estimated |
| Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBDNCT07652294 | SPY001, SPY002, SPY003 | Enrolling by invitation | 2029-03-02Estimated |
| A Study of SPY072 in Rheumatic DiseaseNCT07148414 | SPY002-072 | Active not recruiting | 2026-10-31Estimated |
Names as written in the registry records.
NCT07012395 · Spyre Therapeutics, Inc.
Before: Jun 2026. After: Jun 2027.
NCT07652294 · Spyre Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To assess the safety and tolerability of study drug treatment regimens. After: Measure: Percentage of participants who experienced an adverse event.
NCT07148414 · Spyre Therapeutics, Inc.
Before: Recruiting. After: Active not recruiting.